Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Role of Cerebellum and Prefrontal Cortex in Memory01:14

Role of Cerebellum and Prefrontal Cortex in Memory

The cerebellum, while traditionally associated with motor control, also plays a crucial role in memory, particularly in procedural memory, which involves learning motor tasks that become automatic through repetition. For example, studies have shown that when the cerebellum is damaged, individuals or animals lose the ability to learn conditioned motor responses, such as the conditioned eye-blink response in classical conditioning experiments with rabbits. This study demonstrates the cerebellum's...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mixed-methods feasibility study of a community-based model to improve equity and efficiency in dementia research participation: protocol for ACCESS D.

BMJ open·2026
Same author

A real-world feasibility study: at home longitudinal use of the Cumulus NeuLogiq® platform for electrophysiological and neurocognitive measures in patients with mild Alzheimer's Disease dementia.

Frontiers in digital health·2026
Same author

Identifying microbial biomarkers of neurodegeneration: a comparative study in Alzheimer's and Parkinson's disease.

Frontiers in microbiomes·2026
Same author

REMOTE-Neuro: co-produced recommendations to optimise remote neurology.

BMJ neurology open·2026
Same author

Corrigendum to "Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes" [The Journal of Prevention of Alzheimer's Disease (2026) 100507].

The journal of prevention of Alzheimer's disease·2026
Same author

Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes.

The journal of prevention of Alzheimer's disease·2026

Related Experiment Video

Updated: Jun 28, 2026

Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
06:46

Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage

Published on: August 4, 2018

Executive function in progressive and nonprogressive behavioral variant frontotemporal dementia.

Michael Hornberger1, Olivier Piguet, Christopher Kipps

  • 1Prince of Wales Medical Research Institute, Randwick, Sydney, NSW, Australia.

Neurology
|November 5, 2008
PubMed
Summary

Behavioral variant frontotemporal dementia (bv-FTD) patients who progress show executive task impairments. Differentiating progressive from nonprogressive bv-FTD requires specific executive function tests, not just behavioral changes.

More Related Videos

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis
07:00

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis

Published on: October 13, 2016

Related Experiment Videos

Last Updated: Jun 28, 2026

Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
06:46

Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage

Published on: August 4, 2018

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis
07:00

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis

Published on: October 13, 2016

Area of Science:

  • Neuroscience
  • Neurology
  • Cognitive Science

Background:

  • Behavioral variant frontotemporal dementia (bv-FTD) exhibits variable patient prognoses, with distinct fast-progressing and very slow-progressing cases.
  • Identifying reliable diagnostic markers is crucial for distinguishing between progressive and nonprogressive bv-FTD trajectories.

Purpose of the Study:

  • To investigate the executive and behavioral profiles of progressive and nonprogressive bv-FTD patients.
  • To establish diagnostic markers capable of discriminating between these two patient groups.

Main Methods:

  • Utilized a comprehensive suite of neuropsychological and behavioral tests.
  • Applied mean overlap-based statistical analyses and logistic regression to differentiate progressive from nonprogressive bv-FTD cases.

Main Results:

  • Progressive and nonprogressive bv-FTD patients displayed similar behavioral profiles but differed significantly in executive task performance.
  • Progressors consistently showed impairments in Digit Span Backward, Hayling Test of inhibitory control, Letter Fluency, and Trails B, while nonprogressors performed within normal limits.
  • Logistic regression analysis achieved 86% accuracy in classifying patients based on Digit Span and Hayling subscores.

Conclusions:

  • Contrary to some previous findings, progressing bv-FTD patients typically present with executive task impairments.
  • A notable minority of true bv-FTD patients may exhibit normal performance on executive tasks at initial presentation.
  • Discrepancies in prior research may stem from the inclusion of both progressing FTD patients and phenocopy cases.